Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma

Immunotherapy treatments, particularly immune checkpoint blockade, can result in benefits in clinical settings. But many pre-clinical and clinical studies have shown that resistance to anti-PD1 therapy frequently occurs, leading to tumor recurrence and treatment failure, including in patients with h...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Xiangyi, Zheng, Zhiying, Song, Guoxin, Zhang, Zihao, Liu, Hanyuan, Kang, Junwei, Sun, Guoqiang, Sun, Guangshun, Huang, Tian, Li, Xiao, Rong, Dawei, Wang, Ke, Tang, Weiwei, Xia, Yongxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257027/
https://www.ncbi.nlm.nih.gov/pubmed/35812439
http://dx.doi.org/10.3389/fimmu.2022.876048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257027/
https://www.ncbi.nlm.nih.gov/pubmed/35812439
http://dx.doi.org/10.3389/fimmu.2022.876048

Ejemplares similares